Greywolf Therapeutics and Genomics Launch Strategic Relationship to Develop First‑in‑Class Treatments for Autoimmune Diseases

Contributed by: PR Newswire

Tags

Genomics-Greywolf

More Like This

Greywolf Therapeutics reports durable clinical responses with first-in-class oral ERAP1 inhibitor GRWD5769 across six solid tumor types

PR Newswire associated0

Werfen Receives CE Mark for Aptiva® Antiphospholipid Syndrome Reagents

PR Newswire associated0

EpilepsyGTx and Viralgen collaborate to advance AAV gene therapy programme for epilepsy ahead of first-in-human trial

Egle Therapeutics to share preclinical data for its first autoimmune disease program, EGL-003, with an oral presentation at the 2024 Promise of Interleukin-2 Therapy Meeting

Tanner Pharma Group and Biodexa Launch Global Early Access Program for FAP Patients

PR Newswire associated0

Werfen Announces US FDA 510(k) Clearance and CE Mark for Aptiva® Antiphospholipid Syndrome IgA Reagent

BioMed X Launches a New Call for Application in Autoimmune Disease Research

Parse Biosciences and Graph Therapeutics Partner to Build Large Functional Immune Perturbation Atlas